Overview
- The serum went on sale Thursday direct to consumers, with a rollout to clinics in the U.K., Europe and Australia at $96 or £79.
- The formula swaps salmon-derived PDRN for a bacteria-derived, tetrahedral version that the brand says absorbs better, plus a triple exosome mix reported at up to 151 billion per vial.
- Medik8 cites an independent two-week study showing visible improvements in skin volume and wrinkles after use.
- Early customer ratings and tester reports are largely positive on glow, hydration and redness, though some users saw little change in fine lines.
- Research for topical PDRN remains limited compared with injectable treatments, and in-clinic availability in the United States has not been announced.